Human Placenta-Derived Mesenchymal Stem Cell Transplantation in Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19: Phase I Clinical Trial)

Modiriat Atiye Bahman Company0 个研究点目标入组 20 人开始时间: 待定最近更新: 2021年2月22日

试验速览

暂无简介。

•COVID-19 infection confirmed with positive PCR test results with clinical signs including respiratory distress, cough, fever, decreased blood oxygen saturation, and imaging results in favor of ARDS
•Over 18 years of age
•Bilateral opacity of lungs on CT scan
•PaO2/FiO2 ratio < 200
•Requires mechanical ventilation to increase oxygen saturation
•Written informed consent (according to the patient's condition, in case of unconscious consent, the consent will be obtained from the patient's guardian).

•Less than 18 years of age
•More than 96 hours passed from the diagnosis of ARDS (Based on the Berlin definition of ARDS)
•Pregnancy or breastfeeding
•Presence of active malignancy which has been treated in the past two years
•Presence of severe and irreversible disease with a life expectancy of less than 6 months
•Moderate to severe liver failure (Childs-Pugh Score> 12)
•History of chronic lung disease with PaCO2>50 mm Hg or history of oxygen consumption at home
•Extensive trauma in the past 5 days
•History of lung transplantation
•Inability to provide informed consent or meet test conditions
•Class 3 or 4 pulmonary hypertension (WHO classification)
•History of pulmonary embolism or deep vein thrombosis (DVT) in the past three months

发起方

Modiriat Atiye Bahman Company